Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 17

1.

Examination of the mechanism of action of two pre-quit pharmacotherapies for smoking cessation.

Ferguson SG, Walters JA, Lu W, Wells GP, Schüz N.

BMC Public Health. 2015 Dec 21;15:1268. doi: 10.1186/s12889-015-2596-2.

2.

Amitifadine, a triple monoamine re-uptake inhibitor, reduces nicotine self-administration in female rats.

Levin ED, Wells C, Johnson JE, Rezvani AH, Bymaster FP, Rose JE.

Eur J Pharmacol. 2015 Oct 5;764:30-7. doi: 10.1016/j.ejphar.2015.06.041.

3.

IV nicotine self-administration in rats using a consummatory operant licking response: sensitivity to serotonergic, glutaminergic and histaminergic drugs.

Cousins V, Rose JE, Levin ED.

Prog Neuropsychopharmacol Biol Psychiatry. 2014 Oct 3;54:200-5. doi: 10.1016/j.pnpbp.2014.06.004.

4.

Convergent pharmacological mechanisms in impulsivity and addiction: insights from rodent models.

Jupp B, Dalley JW.

Br J Pharmacol. 2014 Oct;171(20):4729-66. doi: 10.1111/bph.12787. Review.

5.

ABT-089 and ABT-894 reduce levodopa-induced dyskinesias in a monkey model of Parkinson's disease.

Zhang D, Bordia T, McGregor M, McIntosh JM, Decker MW, Quik M.

Mov Disord. 2014 Apr;29(4):508-17. doi: 10.1002/mds.25817.

6.

Nicotine reduces established levodopa-induced dyskinesias in a monkey model of Parkinson's disease.

Quik M, Mallela A, Ly J, Zhang D.

Mov Disord. 2013 Sep;28(10):1398-406. doi: 10.1002/mds.25594.

7.

Serotonin transporter and receptor genes significantly impact nicotine dependence through genetic interactions in both European American and African American smokers.

Yang Z, Seneviratne C, Wang S, Ma JZ, Payne TJ, Wang J, Li MD.

Drug Alcohol Depend. 2013 May 1;129(3):217-25. doi: 10.1016/j.drugalcdep.2012.12.007.

8.

Nicotine-mediated improvement in L-dopa-induced dyskinesias in MPTP-lesioned monkeys is dependent on dopamine nerve terminal function.

Quik M, Mallela A, Chin M, McIntosh JM, Perez XA, Bordia T.

Neurobiol Dis. 2013 Feb;50:30-41. doi: 10.1016/j.nbd.2012.09.006.

9.

5-HT(2A) receptor blockade and 5-HT(2C) receptor activation interact to reduce cocaine hyperlocomotion and Fos protein expression in the caudate-putamen.

Pockros LA, Pentkowski NS, Conway SM, Ullman TE, Zwick KR, Neisewander JL.

Synapse. 2012 Dec;66(12):989-1001. doi: 10.1002/syn.21592.

10.

Brain regions mediating α3β4 nicotinic antagonist effects of 18-MC on nicotine self-administration.

Glick SD, Sell EM, McCallum SE, Maisonneuve IM.

Eur J Pharmacol. 2011 Nov 1;669(1-3):71-5. doi: 10.1016/j.ejphar.2011.08.001.

11.

Lorcaserin, a 5-HT2C agonist, decreases nicotine self-administration in female rats.

Levin ED, Johnson JE, Slade S, Wells C, Cauley M, Petro A, Rose JE.

J Pharmacol Exp Ther. 2011 Sep;338(3):890-6. doi: 10.1124/jpet.111.183525.

12.

The monoamine oxidase (MAO) inhibitor tranylcypromine enhances nicotine self-administration in rats through a mechanism independent of MAO inhibition.

Lotfipour S, Arnold MM, Hogenkamp DJ, Gee KW, Belluzzi JD, Leslie FM.

Neuropharmacology. 2011 Jul-Aug;61(1-2):95-104. doi: 10.1016/j.neuropharm.2011.03.007.

13.

Differential effects of 5-HT(2A) and 5-HT(2C) receptor blockade on strategy-switching.

Baker PM, Thompson JL, Sweeney JA, Ragozzino ME.

Behav Brain Res. 2011 May 16;219(1):123-31. doi: 10.1016/j.bbr.2010.12.031.

14.

D-cycloserine selectively decreases nicotine self-administration in rats with low baseline levels of response.

Levin ED, Slade S, Wells C, Petro A, Rose JE.

Pharmacol Biochem Behav. 2011 Apr;98(2):210-4. doi: 10.1016/j.pbb.2010.12.023.

15.

Serotonergic mechanism underlying tranylcypromine enhancement of nicotine self-administration.

Villégier AS, Belluzzi JD, Leslie FM.

Synapse. 2011 Jun;65(6):479-89. doi: 10.1002/syn.20864.

16.

Affinity of aporphines for the human 5-HT2A receptor: insights from homology modeling and molecular docking studies.

Pecic S, Makkar P, Chaudhary S, Reddy BV, Navarro HA, Harding WW.

Bioorg Med Chem. 2010 Aug 1;18(15):5562-75. doi: 10.1016/j.bmc.2010.06.043.

17.

(+/-)-Nantenine analogs as antagonists at human 5-HT(2A) receptors: C1 and flexible congeners.

Chaudhary S, Pecic S, Legendre O, Navarro HA, Harding WW.

Bioorg Med Chem Lett. 2009 May 1;19(9):2530-2. doi: 10.1016/j.bmcl.2009.03.048.

Supplemental Content

Support Center